Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesp - Bloomberg
Links shared publicly online about this topic.
- 870total visits
Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesp - Bloomberg
Diabetic patients with chronic kidney disease are more likely to suffer heart complications or die if they need higher doses of Amgen Inc. 's Aranesp to reach current treatment goals, researchers said.
View full resource at bloomberg.com
Tags: Heart, Anemia Medication, Diabetes, Urinary System, End-Stage Renal Disease, Aranesp, Amgen, Chronic Kidney Disease
Most Recently Shared on September 16, 2010 at 9:56 am By:
Heart Risks Rise for Kidney Patients on Higher Doses of Amgen's Aranesphttp://bit.ly/bEsq28
Advertisement
